These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9231891)

  • 21. HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs.
    Seravalle G; Koylan N; Nalbantgil I; Caglar N; Quarti-Trevano F; Makel W; Grassi G; Fici F
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):165-72. PubMed ID: 25900022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertension and vascular disease in the 1990s.
    Gorlin R
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV1-5; discussion IV51-5. PubMed ID: 1893637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
    Ovchinnikov AG; Serbul VM; Ageev FT
    Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S; Arora RR
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of combination therapy on regression of left ventricular hypertrophy in cases with hypertension.
    Boydak B; Nalbantgil S; Yilmaz H; Zoghi M; Ozerkan F; Nalbantgil I; Onder R
    Saudi Med J; 2004 Dec; 25(12):1975-8. PubMed ID: 15711679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of cardiac hypertrophy by 1,4 dihydropyridines in hypertensive patients.
    Leenen FH
    J Hypertens Suppl; 1998 Oct; 16(5):S9-15. PubMed ID: 9868999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
    Dahlöf B
    J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Retrospective studies and prospects of therapy for hypertension].
    Maisch B; Brilla C; Kruse T; Noll B; Bethge C
    Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Present-day treatment of arterial hypertension].
    Schuchert A
    Med Monatsschr Pharm; 2010 Dec; 33(12):462-8: quiz 469-70. PubMed ID: 21189521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of hypertension, Part II.
    Moser M
    Am Fam Physician; 1996 Jun; 53(8):2553-60. PubMed ID: 8644569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
    Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence?
    Taddei S
    Am J Cardiovasc Drugs; 2015 Jun; 15(3):185-94. PubMed ID: 25850749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.